Boston Scientific Corp.

Marlborough-based Boston Scientific Corp. has completed its acquisition of American Medical Systems' (AMS) Men's Health and Prostate Health businesses for $1.6 billion.

A 2.3-percent tax doesn't sound like much, but taking it directly off the top of medical device companies' sales could have widespread impacts on businesses large and small, industry experts say.

Paul Reilly is a firm believer in fitness, from his days at West Point to his current role as CEO of a Westborough-based company that helps senior citizens stay in shape.

Marlborough-based Boston Scientific saw its operational revenue and profits rise in the second quarter, the company reported Thursday. The results are at the upper end of the company's guidance range.

In May, Marlborough-based Boston Scientific Corp. lost a $100 million verdict in a case over its transvaginal...

Boston Scientific is offering $1.85 billion in bonds to help finance a recent acquisition and pay down previously issued debt, the Marlborough-based medical device manufacturer announced Thursday.

Marlborough-based Boston Scientific Corp. reported adjusted first-quarter earnings of 21 cents per share Tuesday, a penny higher than for the first quarter of 2014, and at the high end of the company's projection of 19 to 21 cents.

Boston Scientific has aligned itself with a Chinese company that will help the Marlborough-based medical device manufacturer reach out to more doctors in that country who remove stones from patients' bile ducts.

Taking Stock, a new feature in the Worcester Business Journal, will be published quarterly to highlight the market performance of public companies that are either based or that have a significant presence in Central Massachusetts.

Marlborough-based medical device manufacturer Boston Scientific has reached an agreement to acquire Xlumena Inc. Based in Mountain View, Calif., Xlumena makes minimally invasive devices to drain targeted areas of the gastrointestinal tract through endoscopic ultrasound. The deal is valued at $75 million and was expected to close this week, Boston Scientific (BSX) said in a statement Wednesday afternoon.